Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 15.4% in March

Structure Therapeutics Inc. (NASDAQ:GPCR) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,740,000 shares, an increase of 15.4% from the March 15th total of 3,240,000 shares. Currently, 9.0% of the shares of the company are short sold. Based on an average daily volume of 584,800 shares, the days-to-cover ratio is currently 6.4 days.

Structure Therapeutics Stock Performance

GPCR traded up $0.17 during trading on Tuesday, hitting $37.82. The stock had a trading volume of 248,543 shares, compared to its average volume of 582,014. The firm has a market capitalization of $1.76 billion and a P/E ratio of -45.57. The company’s 50-day moving average price is $41.21 and its 200 day moving average price is $48.78. Structure Therapeutics has a twelve month low of $21.79 and a twelve month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. As a group, equities analysts expect that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GPCR shares. Lifesci Capital reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald started coverage on shares of Structure Therapeutics in a research report on Tuesday, April 9th. They issued an “overweight” rating and a $65.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $85.71.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Steward Partners Investment Advisory LLC acquired a new position in shares of Structure Therapeutics during the 4th quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of Structure Therapeutics by 1,274.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 921 shares of the company’s stock worth $46,000 after purchasing an additional 854 shares during the period. Barclays PLC acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth $47,000. Picton Mahoney Asset Management acquired a new position in shares of Structure Therapeutics during the 3rd quarter worth $116,000. Finally, Sectoral Asset Management Inc. acquired a new position in shares of Structure Therapeutics during the 4th quarter worth $139,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.